Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma
STOCKHOLM — December 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of ...